Non trouvé

1Mo·

$BNTX (-2 %) Could BioNTech become one of the top picks for 2025?

If the results of the current studies are confirmed, BioNTech could launch the first cancer therapies on the market in 2026. You can imagine what that means. That would give the share a strong boost🚀

Even though the share price has already moved quite a bit away from the lows in the summer, it is still an interesting level!

Daily chart:

Weekly chart:

BioNTech exhibits "OUTSTANDING" financial health, supported by strong cash flow metrics.

According to BMO Capital, the safety profile of BNT324 is in line with other ADCs currently available on the market. BioNTechs
strong
financial
positionwith more cash than debt and a healthy liquidity ratio of 7.33, provides robust support for its drug development initiatives. In addition, they highlighted that the drug showed promising early efficacy results, particularly in patients with small cell lung cancer (SCLC).

BioNTech's continued Outperform rating reflects confidence in the drug's potential and its alignment with the company's development goals.

I have BioNTech in my portfolio and it is also one of the few individual stocks in my children's portfolios - the time factor plays into their hands anyway 😎🏦

Source: https://de.investing.com/news/analyst-ratings/bmo-halt-an-outperformbewertung-fur-biontechaktien-fest-93CH-2796832

8 Commentaires

ThemenmitKopf@topicswithhead

1Mo

Unfortunately, I made a large partial sale and only have 1 share left. Notwithstanding this, I have reported positively often enough and consider it a blatant buy candidate. They only suffer from the image of the mRNA vaccination and the associated opinion on Corona. Nevertheless, the technology is very good and so is the pipeline. They also have a unique AI department and stable anchor shareholders. So basically it's just the uncertainty, Germany mRNA where the uncertainty wasn't the problem for me now

•

TomTurboInvest@TomTurboInvest

1Mo

@topicswithhead Well, if you always knew beforehand 😅
I topped up at €85 in March and May, and at €82 in June. But it could also have been a case of falling into a knife.

And the skepticism about mRNA and vaccinations in general will be of little interest to those affected. Unfortunately, there are enough of them, and every straw is a chance to prolong life. Nothing is as final as death 😥

What many people don't realize is that the pharmaceutical research sector in general was and still is an early driver for AI. BioNTech is also very well positioned in this area.

•

ThemenmitKopf@topicswithhead

1Mo

@TomTurboInvest Don't get me wrong. I didn't sell too early, I sold right at the high. It still annoys me because I would have liked to have a few more shares. I just had to liquidate money for something else. Hence the 1 share to follow

•

TomTurboInvest@TomTurboInvest

1Mo

@topicswithhead But if you have caught the high well, then you will also be very pleased with a current entry, because you can buy them again at a much lower price.

I also sold mine near the high, but then got back in too early, but thanks to the additional purchases I now have a buy-in of €99 again - the psychological <€100 is good 🤪

••

ThemenmitKopf@topicswithhead

1Mo

@TomTurboInvest I want in, but then my entry price would no longer be 79 but just under 100, so I want to wait for 99.99 as well. At least that still gives me a good feeling

•

TomTurboInvest@TomTurboInvest

1Mo

@topicswithhead Given the volatility of the last few months, this could happen again, if so - then I'll add more 💰

•

ThemenmitKopf@topicswithhead

1Mo

@TomTurboInvest only believe if through the election or an escalation. We are slowly approaching the first drugs and retail investors are also losing their fear of investing. My plan is to have the first successes in 2025/2026.

•

Marcie@Marcie

1Mo

I've had a savings plan for about a year now and it's developed quite well. Unfortunately not a large sum 🤷🏼‍♂️.

But I'm also looking forward to 25/26

•